LXEOLexeo Therapeutics, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$109M
- 3.3% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired19× of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|
| Revenue | $654K | — | — | — | |
| Operating income | −$61M | −$69M | −$106M | −$109M | 3.3% |
| Net income | −$59M | −$66M | −$98M | −$100M | 1.7% |
| Operating cash flow | −$55M | −$59M | −$81M | −$99M | 21% |
| Capex | $672K | $115K | $481K | $397K | 17% |
| Stock-based comp | $2M | $3M | $12M | $12M | 2.7% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $19K · 1
- Net
- −$19K
Pay vs performance
No pay-versus-performance disclosure yet.